{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:35:36Z","timestamp":1777955736823,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmaceutica SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ad.2025.104582","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:07:35Z","timestamp":1766246855000},"page":"104582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa"],"prefix":"10.1016","volume":"117","author":[{"given":"A.","family":"Martorell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jim\u00e9nez Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-0115","authenticated-orcid":false,"given":"C.","family":"Blanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104582_bib0150","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104582_bib0155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ad.2025.104582_bib0160","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2025.104582_bib0165","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2025.104582_bib0170","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Amat-Samaranch","year":"2021","journal-title":"Ther Adv Chron Dis"},{"key":"10.1016\/j.ad.2025.104582_bib0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.104582_bib0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CCID.S391356","article-title":"Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience","volume":"16","author":"Martora","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2025.104582_bib0185","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104582_bib0190","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2018.05.015","article-title":"Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials","volume":"79","author":"Kimball","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104582_bib0195","unstructured":"European Medicines Agency. Cosentyx\u00ae (secukinumab): summary of product characteristics [cited Oct 2024]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf."},{"key":"10.1016\/j.ad.2025.104582_bib0200","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2025.104582_bib0205","article-title":"Economic analysis of the costs associated with hidradenitis suppurativa at a German University Hospital","volume":"16","author":"Frings","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ad.2025.104582_bib0210","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14737167.2021.1895753","article-title":"Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study","volume":"22","author":"G\u00e1sp\u00e1r","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ad.2025.104582_bib0215","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104582_bib0220","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Prodcutos Sanitarios. Ficha tecnica Cosentyx [cited Oct 2024]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/114980004\/FT_114980004.html."},{"key":"10.1016\/j.ad.2025.104582_bib0225","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Prodcutos Sanitarios. Ficha tecnica Humira [cited Oct 2024]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/103256017\/FT_103256017.html."},{"key":"10.1016\/j.ad.2025.104582_bib0230","unstructured":"Ministerio de Sanidad. BIFIMED: Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos [cited Oct 2024]. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do."},{"key":"10.1016\/j.ad.2025.104582_bib0235","series-title":"Resoluci\u00f3n de adjudicaci\u00f3n No. 121\/2023","year":"2023"},{"key":"10.1016\/j.ad.2025.104582_bib0240","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Bot Plus Web [cited Oct 2024]. Available from: https:\/\/botplusweb.portalfarma.com\/."},{"key":"10.1016\/j.ad.2025.104582_bib0245","unstructured":"Estudio de mercado de ACOBUR. Novartis 2022 Data on file."},{"key":"10.1016\/j.ad.2025.104582_bib0250","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/09546634.2017.1364687","article-title":"Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service","volume":"28","author":"Puig","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.104582_bib0255","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.reuma.2020.05.004","article-title":"A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis","volume":"17","author":"Jim\u00e9nez-Morales","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ad.2025.104582_bib0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104582_bib0265","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.17551","article-title":"Improvement in hidradenitis suppurativa and quality of life in patients treated with adalimumab: real-world results from the HARMONY study","volume":"35","author":"Hafner","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104582_bib0270","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.17101","article-title":"Impact of hidradenitis suppurativa on work loss, indirect costs and income","volume":"181","author":"Tzellos","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104582_bib0275","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40257-023-00796-2","article-title":"Disease burden and treatment patterns among US patients with hidradenitis suppurativa: a retrospective cohort study","volume":"24","author":"Garg","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.104582_bib0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","article-title":"Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes","volume":"14","author":"Kimball","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104582_bib0285","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/bjd\/ljae098","article-title":"Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials","volume":"190","author":"Zouboulis","year":"2024","journal-title":"Br J Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.ad.2025.104582_bib0290","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0001-7310(17)30007-8","article-title":"Management of patients with hidradenitis suppurativa","volume":"107","author":"Martorell","year":"2016","journal-title":"Actas Dermosifiliogr"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:33:40Z","timestamp":1777937620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025008580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0001731025008580"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104582","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104582"}}